1-6 of 6
Cherrie K. Donawho
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody

Free
Edward B. Reilly, Andrew C. Phillips, Fritz G. Buchanan, Gillian Kingsbury, Yumin Zhang, Jonathan A. Meulbroek, Todd B. Cole, Peter J. DeVries, Hugh D. Falls, Christine Beam, Jinming Gu, Enrico L. Digiammarino, Joann P. Palma, Cherrie K. Donawho, Neal C. Goodwin, Andrew M. Scott
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (5): 1141–1151.
https://doi.org/10.1158/1535-7163.MCT-14-0820
Published: 05 May 2015
View articletitled, Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody
Open the PDF for Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody in another window
Journal Articles

Abstract B62: Potent single agent in vivo activity of the PARP inhibitor veliparib (ABT-888) in BRCA-deficient xenografts (MX-1 and Capan-1).

Free
Cherrie K. Donawho, Luis E. Rodriguez, Paul A. Ellis, Lance Kaleta, Gail Bukofzer, Velitchka Bontcheva-Diaz, Xuesong Liu, Jennifer Bouska, Robert Carr, Kenneth Idler, Guidong Zhu, Thomas Penning, Alexander Shoemaker, Vincent L. Giranda, Fritz Buchanan, David J. Frost, Joann P. Palma
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B62.
https://doi.org/10.1158/1535-7163.TARG-11-B62
Published: 12 November 2011
View articletitled, Abstract B62: Potent single agent in vivo activity of the PARP inhibitor veliparib (ABT-888) in BRCA-deficient xenografts (MX-1 and Capan-1).
Journal Articles

Abstract B231: Potent in vivo activity of the Aurora kinase inhibitor ABT-348 in a broad spectrum of histological types: Evaluation of efficacy, dosing/scheduling, and PK/PD.

Free
Cherrie K. Donawho, Debra Montgomery, Luis E. Rodriguez, Yi-Chun Wang, Paul E. Ellis, Lance Kaleta, Gail Bukofzer, Jennifer Bouska, Jerry Clarin, Sally Schlessinger, Baole Wang, Keith Glaser, Mike Michaelides, Daniel Albert, Chris Tse, David J. Frost, Joann P. Palma
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B231.
https://doi.org/10.1158/1535-7163.TARG-11-B231
Published: 12 November 2011
View articletitled, Abstract B231: Potent in vivo activity of the Aurora kinase inhibitor ABT-348 in a broad spectrum of histological types: Evaluation of efficacy, dosing/scheduling, and PK/PD.
Journal Articles

Abstract A239: Preclinical characterization of ABT-348, a kinase inhibitor targeting the Aurora, VEGFR/PDGFR, and SRC kinase families.

Free
Keith B. Glaser, Junling Li, Patrick A. Marcotte, Terrance J. Magoc, Jun Guo, David R. Reuter, Paul Tapang, Ru-Qi Wei, Lori J. Pease, Mai H. Bui, Zehan Chen, Robin R. Frey, Eric F. Johnson, Donald J. Osterling, Amanda M. Olson, Jennifer J. Bouska, Michael L. Curtin, Cherrie K. Donawho, Michael R. Michaelides, Chris Tse, Steven K. Davidsen, Daniel H. Albert
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A239.
https://doi.org/10.1158/1535-7163.TARG-11-A239
Published: 12 November 2011
View articletitled, Abstract A239: Preclinical characterization of ABT-348, a kinase inhibitor targeting the Aurora, VEGFR/PDGFR, and SRC kinase families.
Journal Articles

Abstract B14: The broad spectrum antitumor efficacy and tolerability of the RTK inhibitor, linifanib (ABT‐869) alone and in combination with various cytotoxic therapies

Free
Cherrie K. Donawho, Gail Bukofzer, Paul A. Ellis, Debra A. Montgomery, Luis E. Rodriguez, Yi‐Chun Wang, Yujia Dai, Steven K. Davidsen, David J. Frost, Joann P. Palma
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B14.
https://doi.org/10.1158/1535-7163.TARG-09-B14
Published: 10 December 2009
View articletitled, Abstract B14: The broad spectrum antitumor efficacy and tolerability of the RTK inhibitor, linifanib (ABT‐869) alone and in combination with various cytotoxic therapies
Journal Articles

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor

Free
Daniel H. Albert, Paul Tapang, Terrance J. Magoc, Lori J. Pease, David R. Reuter, Ru-Qi Wei, Junling Li, Jun Guo, Peter F. Bousquet, Nayereh S. Ghoreishi-Haack, Baole Wang, Gail T. Bukofzer, Yi-Chun Wang, Jason A. Stavropoulos, Kresna Hartandi, Amanda L. Niquette, Nirupama Soni, Eric F. Johnson, J. Owen McCall, Jennifer J. Bouska, Yanping Luo, Cherrie K. Donawho, Yujia Dai, Patrick A. Marcotte, Keith B. Glaser, Michael R. Michaelides, Steven K. Davidsen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (4): 995–1006.
https://doi.org/10.1158/1535-7163.MCT-05-0410
Published: 28 April 2006
View articletitled, Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor
Open the PDF for Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor in another window